Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 5597-5603, October 15, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Testa, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Testa, J. E.

Loss of the Metastatic Phenotype by a Human Epidermoid Carcinoma Cell Line, HEp-3, Is Accompanied by Increased Expression of Tissue Inhibitor of Metalloproteinase 21

Jacqueline E. Testa2

Department of Pathology, State University of New York, Stony Brook, New York 11794

The human epidermoid carcinoma cell line HEp-3 gives rise to spontaneous metastases in nude mice and in the chick chorioallantoic membrane (CAM) assay system. Cells passaged continuously on the CAM retain their ability to form metastases, while cells carried in vitro lose metastatic potential with time. A HEp-3 cell line derived from a highly metastatic CAM tumor was grown continuously in vitro for 16 weeks. At 2-week intervals the cells were tested on the CAM for metastatic ability and assayed for expression of urokinase-type plasminogen activator (uPA) and the Mr 92,000 and Mr 72,000 gelatinase/type IV collagenases, enzymes the expression of which has previously been shown to correlate with tumor cell dissemination. Expression of proteins which modulate the degradative potential of these enzymes, plasminogen activator inhibitors 1 and 2 (PAI-1, PAI-2), uPA receptor, and tissue inhibitors of metalloproteases 1 and 2 (TIMP-1 and TIMP-2), were also assayed. As previously reported the metastatic ability of these cells decreased with time in culture and was almost completely lost by 8 weeks in vitro. Secreted uPA activity remained essentially unchanged, even though uPA mRNA levels decreased with time. There was also a decrease in PAI-1 and PAI-2 mRNA. However, PAI-1 protein concentration in conditioned medium remained relatively constant, and only trace amounts of PAI-2 protein could be detected in cell lysates. Steady-state levels of uPA receptor were lowest at 2 weeks then increased sharply at 4 weeks and remained relatively constant thereafter. A decrease in secreted Mr 92,000 and Mr 72,000 gelatinase activities and their corresponding mRNAs was observed well after the loss of the metastatic phenotype. During the 16 weeks in culture TIMP-1 mRNA levels changed slightly, while TIMP-2 mRNA increased more than 2-fold. These data suggest that a metalloproteinase other than the gelatinase/type IV collagenases may be involved in HEp-3 metastasis.

1 Supported by Grants IN164 and IN164B from the American Cancer Society, JFRA-265 from the American Cancer Society (awarded to J. E. T.), and IM 565 from the American Cancer Society (awarded to J. P. Q.).

2 To whom requests for reprints should be addressed.

Received 8/13/91. Accepted 8/10/92.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. R. Nair, J. Solway, and D. D. Boyd
Expression Cloning Identifies Transgelin (SM22) as a Novel Repressor of 92-kDa Type IV Collagenase (MMP-9) Expression
J. Biol. Chem., September 8, 2006; 281(36): 26424 - 26436.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Zijlstra, R. Mellor, G. Panzarella, R. T. Aimes, J. D. Hooper, N. D. Marchenko, and J. P. Quigley
A Quantitative Analysis of Rate-limiting Steps in the Metastatic Cascade Using Human-specific Real-Time Polymerase Chain Reaction
Cancer Res., December 1, 2002; 62(23): 7083 - 7092.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. E. Testa, P. C. Brooks, J.-M. Lin, and J. P. Quigley
Eukaryotic Expression Cloning with an Antimetastatic Monoclonal Antibody Identifies a Tetraspanin (PETA-3/CD151) as an Effector of Human TumorCell Migration and Metastasis
Cancer Res., August 1, 1999; 59(15): 3812 - 3820.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
G Cox, W P Steward, and K J O'Byrne
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer
Thorax, February 1, 1999; 54(2): 169 - 179.
[Full Text]


Home page
Circ. Res.Home page
D. Hasenstab, R. Forough, and A. W. Clowes
Plasminogen Activator Inhibitor Type 1 and Tissue Inhibitor of Metalloproteinases-2 Increase After Arterial Injury in Rats
Circ. Res., April 19, 1997; 80(4): 490 - 496.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.